NASDAQ:ACON Aclarion (ACON) Stock Price, News & Analysis $6.59 -0.30 (-4.35%) Closing price 04:00 PM EasternExtended Trading$6.62 +0.04 (+0.53%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Aclarion Stock (NASDAQ:ACON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aclarion alerts:Sign Up Key Stats Today's Range$6.38▼$6.9550-Day Range$6.39▼$20.7952-Week Range$6.20▼$3,499.51Volume30,342 shsAverage Volume56,925 shsMarket Capitalization$3.84 millionP/E RatioN/ADividend YieldN/APrice Target$11,758.50Consensus RatingModerate Buy Company OverviewAclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Read More… Aclarion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreACON MarketRank™: Aclarion scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAclarion has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAclarion has received no research coverage in the past 90 days.Read more about Aclarion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclarion are expected to grow in the coming year, from ($263.33) to ($216.67) per share. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.35% of the float of Aclarion has been sold short.Short Interest Ratio / Days to CoverAclarion has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclarion has recently decreased by 71.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclarion does not currently pay a dividend.Dividend GrowthAclarion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.35% of the float of Aclarion has been sold short.Short Interest Ratio / Days to CoverAclarion has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclarion has recently decreased by 71.40%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.96 News SentimentAclarion has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aclarion this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aclarion insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.77% of the stock of Aclarion is held by insiders.Percentage Held by InstitutionsOnly 7.52% of the stock of Aclarion is held by institutions.Read more about Aclarion's insider trading history. Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address ACON Stock News HeadlinesAclarion (NASDAQ:ACON) Stock Price Down 1.2% - Here's What HappenedMay 22, 2025 | americanbankingnews.comAclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial SiteMay 20, 2025 | globenewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 29, 2025 | Porter & Company (Ad)Aclarion Inc Ordinary SharesMay 15, 2025 | morningstar.comAclarion Announces Texas Back Institute as New CLARITY Trial SiteMay 12, 2025 | globenewswire.comAclarion Welcomes Advocate Health as CLARITY Trial SiteMay 5, 2025 | globenewswire.comAclarion Announces Commercial Agreement with Spine Institute of LouisianaApril 29, 2025 | globenewswire.comAclarion files $150M mixed securities shelfApril 26, 2025 | markets.businessinsider.comSee More Headlines ACON Stock Analysis - Frequently Asked Questions How have ACON shares performed this year? Aclarion's stock was trading at $1,302.48 at the beginning of the year. Since then, ACON stock has decreased by 99.5% and is now trading at $6.59. View the best growth stocks for 2025 here. How were Aclarion's earnings last quarter? Aclarion, Inc. (NASDAQ:ACON) posted its earnings results on Thursday, May, 15th. The company reported ($9.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1,447.20) by $1,437.88. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative trailing twelve-month return on equity of 422.87% and a negative net margin of 12,845.05%. When did Aclarion's stock split? Shares of Aclarion reverse split on Friday, March 28th 2025. The 1-27 reverse split was announced on Wednesday, March 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aclarion IPO? Aclarion (ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share. How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclarion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclarion investors own include Broadcom (AVGO), Meta Platforms (META), Norwegian Cruise Line (NCLH), AudioEye (AEYE), Advanced Micro Devices (AMD), ASML (ASML) and AvidXchange (AVDX). Company Calendar Last Earnings5/15/2025Today5/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:ACON CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$11,758.50 High Stock Price Target$11,758.50 Low Stock Price Target$11,758.50 Potential Upside/Downside+175,662.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.91 million Net Margins-12,845.05% Pretax Margin-12,845.05% Return on Equity-422.87% Return on Assets-201.15% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual Sales$54,601.00 Price / Sales71.31 Cash FlowN/A Price / Cash FlowN/A Book Value($125.39) per share Price / Book-0.05Miscellaneous Outstanding Shares582,000Free Float505,000Market Cap$3.89 million OptionableNot Optionable Beta1.13 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ACON) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.